loading page

CAR-T cell therapy in less than 2 year old children with infant acute lymphoblastic leukemia : case reports and review of the literature
  • +7
  • Laurent Cimasoni,
  • Julie Sartoretti,
  • Francesco Ceppi,
  • Shannon Maude,
  • Nicole Bodmer,
  • Mathias Hauri-Hohl,
  • Peter Bader,
  • Frederic Baleydier,
  • Fanette Bernard,
  • Marc Ansari
Laurent Cimasoni
Hôpitaux Universitaires de Genève
Author Profile
Julie Sartoretti
Hôpitaux Universitaires de Genève
Author Profile
Francesco Ceppi
CHUV
Author Profile
Shannon Maude
The Children’s Hospital of Philadelphia
Author Profile
Nicole Bodmer
Universitats-Kinderspital Zurich
Author Profile
Mathias Hauri-Hohl
Universitats-Kinderspital Zurich
Author Profile
Peter Bader
Klinikum der Johann Wolfgang Goethe-Universitat Frankfurt
Author Profile
Frederic Baleydier
Hopitaux Universitaires de Geneve Hopital des enfants
Author Profile
Fanette Bernard
Hôpitaux Universitaires de Genève
Author Profile
Marc Ansari
Hôpital universitaire de Genève
Author Profile

Abstract

Infant acute lymphoblastic leukemia (infant ALL) is known for its poor prognosis. Current treatment protocols include aggressive chemotherapy and allogeneic stem cell transplantation but prognosis remains poor. Immunotherapy is a new approach with promising results. CAR-T cell therapy has recently been approved for relapsed or refractory childhood ALL but lacks documentation regarding infant ALL. We describe here two cases of patients suffering from infant ALL who were treated with CAR-T cell therapy, the feasibility and efficiency of treatment and their outcome.